What changed
$NVO — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $13.6B | EPS $6.63 vs $6.96 🔴
💡 Consensus expects slowing growth and margin compression, but we see resilient volume growth and pipeline progress (e.g., CagriSema) re-accelerating estimates. The miss obscures a durable 20%+ revenue growth trajectory.
📉 Reward/risk: 2.0:1
🏢 Business Quality: 8/10 - Dominant obesity and diabetes franchise with wide moat, sticky demand, and high incremental returns on R&D.
📊 Valuation: cheap — based on normalized forward P/E of 18x vs. historical 22x and peer median 20x; EV/EBITDA 14x vs.
🔮 Catalyst: Oral semaglutide Phase 3 data and CagriSema regulatory update
💰 Entry: $43.19, stop $40.0, target $49.57
⚖️ Buy NVO on post-earnings weakness; the EPS miss is noise against a dominant, underappreciated growth trajectory with near-term pipeline catalysts.
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/NVO0622